Generic-drug-maker Sun Pharmaceutical Industries announced plans to acquire competitor Ranbaxy from Daiichi Sankyo. Ranbaxy has been subject recently to bans on imports of some drugs and pharmaceutical ingredients into the U.S. and is operating under a consent decree with the FDA. Daiichi Sankyo will acquire a 9% share of Sun after the deal closes.

Full Story:

Related Summaries